Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yellow fever vaccine + Japanese encephalitis vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This combination refers to the co-administration or sequential use of the live-attenuated yellow fever vaccine (Stamaril) and the chimeric live-attenuated Japanese encephalitis vaccine (Imojev) in clinical research. Stamaril is a live-attenuated vaccine derived from the 17D strain of the yellow fever virus. Imojev is a recombinant chimeric vaccine that utilizes the YF-17D strain as a genetic backbone, expressing the pre-membrane and envelope proteins of the Japanese encephalitis virus. This specific combination was the subject of a Phase 2 clinical trial at Singapore General Hospital (SGH) titled "Cellular Immunity Correlates with YF17D and JE-YF17D Vaccines." The study aimed to determine if T-cell responses (CD4+ and CD8+) generated by the yellow fever vaccine backbone could reduce viremia upon challenge with the heterologous chimeric Japanese encephalitis vaccine, exploring the concept of cross-reactive cellular immunity between vaccines sharing a common vector backbone.
- Brand names
- StamarilImojev
- Other names
- Stamaril + ImojevYF17D + JE-YF17DStamaril-Singapore General Hospital-Yellow Fever-Japanese Encephalitis
Beyond the preview
Go deeper on yellow fever vaccine + Japanese encephalitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yellow fever vaccine + Japanese encephalitis vaccine.